Home › Research › Biomarkers
Prior Traumatic Brain Injury and Alzheimer Disease Blood Biomarkers
Yael Rosen‐Lang, Agathe Vrillon, Shlomit Pasternak, Ganna Blazhenets, David N. Soleimani‐Meigooni, Gil D. Rabinovici, Michael W. Weiner, Nathan C. Hantke et al.. JAMA Neurology, 2026-06-29
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
In 272 participants, mean (SD) age was 70 (4.5) years, 270 were male (99.3%), and 83 (30.5%) were amyloid-PET positive. The plasma p-tau217/Aβ42 ratio was highly accurate in veterans with no TBI (90%; 95% CI, 84%-96%) but not in veterans with TBI with LOC for 0 to 5 minutes (78% accuracy; 95% CI, 69%-87%; P = .03 vs no TBI), nor in veterans with TBI with LOC greater than 5 minutes (63% accuracy; 95% CI, 53%-73%; P < .001 vs no TBI). Results were similar for plasma p-tau217 alone and plasma Aβ42/40 ratio. Results were also similar after excluding veterans with TBI within the past 10 years or when amyloid-PET positivity was defined using a quantitative threshold rather than consensus visual read. Conclusions and Relevance: Results of this cross-sectional cohort study of a diagnostic test suggest that among individuals who are cognitively unimpaired or have mild cognitive impairment and a TBI history, the p-tau217/Aβ42 ratio test may miss over half of amyloid-PET-positive cases. Caution is advised in interpreting AD blood test results in this context.
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study of 272 participants. The p-tau217/Aβ42 ratio test was accurate in veterans without traumatic brain injury but missed many amyloid-PET-positive cases in those with traumatic brain injury with loss of consciousness. Reported effect size: 99.3%; 30.5%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Rosen‐Lang, Y., Vrillon, A., Pasternak, S., Blazhenets, G., Soleimani‐Meigooni, D. N., Rabinovici, G. D., et al. (2026). Prior Traumatic Brain Injury and Alzheimer Disease Blood Biomarkers. JAMA Neurology. https://doi.org/10.1001/jamaneurol.2026.2042
Vancouver
Rosen‐Lang Y, Vrillon A, Pasternak S, Blazhenets G, Soleimani‐Meigooni DN, Rabinovici GD, et al. Prior Traumatic Brain Injury and Alzheimer Disease Blood Biomarkers. JAMA Neurology. 2026. doi:10.1001/jamaneurol.2026.2042. PMID: 42371653.
BibTeX
@article{rosenlang2026-42371653,
author = {Rosen‐Lang, Yael and Vrillon, Agathe and Pasternak, Shlomit and Blazhenets, Ganna and Soleimani‐Meigooni, David N. and Rabinovici, Gil D. and Weiner, Michael W. and Hantke, Nathan C. and others},
title = {{Prior Traumatic Brain Injury and Alzheimer Disease Blood Biomarkers}},
journal = {JAMA Neurology},
year = {2026},
doi = {10.1001/jamaneurol.2026.2042},
pmid = {42371653},
url = {https://doi.org/10.1001/jamaneurol.2026.2042}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- In 272 participants, mean (SD) age was 70 (4.5) years, 270 were male (99.3%), and 83 (30.5%) were amyloid-PET positive.
- The plasma p-tau217/Aβ42 ratio was highly accurate in veterans with no TBI (90%; 95% CI, 84%-96%) but not in veterans with TBI with LOC for 0 to 5 minutes (78% accuracy; 95% CI, 69%-87%; P = .03 vs no TBI), nor in veterans with TBI with LOC greater than 5 minutes (63% accuracy; 95% CI, 53%-73%; P < .001 vs no TBI).
- Results were similar for plasma p-tau217 alone and plasma Aβ42/40 ratio.
- Results were also similar after excluding veterans with TBI within the past 10 years or when amyloid-PET positivity was defined using a quantitative threshold rather than consensus visual read.
- Conclusions and Relevance: Results of this cross-sectional cohort study of a diagnostic test suggest that among individuals who are cognitively unimpaired or have mild cognitive impairment and a TBI history, the p-tau217/Aβ42 ratio test may miss over half of amyloid-PET-positive cases.
Why it matters
The p-tau217/Aβ42 ratio test was accurate in veterans without traumatic brain injury but missed many amyloid-PET-positive cases in those with traumatic brain injury with loss of consciousness. This is a caution about interpreting this blood test in that group, not a finding about treating or preventing Alzheimer's disease.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designcohort study
- Participants272
- Effect size99.3%; 30.5%
- Evidence strengthModerate
How this study scored 58/100
Published in a leading specialty journal, and it is a cohort study following people over time. Scored zero for randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (JAMA Neurology) |
| Journal's citation record | 2 / 4 | JAMA Neurology: journal h-index 235 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 2 / 4 | 272 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 1 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.5 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 3 / 6 | Cited 4.7× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 0 / 4 | Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Magdalena Korecka: h-index 64 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of California, Berkeley: institution h-index 2,012 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 11 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 42371653) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 58 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 13.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Biomarkers from nearby years
Also tagged “cerebrospinal”
820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.